<?xml version='1.0' encoding='utf-8'?>
<document id="12705168"><sentence text="Interaction between several medicines and statins." /><sentence text="To gain a better understanding of drug-drug interaction between various medicinal substances and statins, in vitro experiments using human hepatic microsomes were performed" /><sentence text=" The metabolic clearance of atorvastatin (CAS 134523-00-5) was about 32 microliters/min/mg protein, some 15-fold greater than that of pitavastatin (CAS 147526-32-7)"><entity charOffset="28-40" id="DDI-PubMed.12705168.s3.e0" text="atorvastatin" /><entity charOffset="134-146" id="DDI-PubMed.12705168.s3.e1" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.12705168.s3.e0" e2="DDI-PubMed.12705168.s3.e0" /><pair ddi="false" e1="DDI-PubMed.12705168.s3.e0" e2="DDI-PubMed.12705168.s3.e1" /></sentence><sentence text=" On co-incubation with several medicinal substances, metabolic inhibition of pitavastatin was negligible in human hepatic microsomes"><entity charOffset="77-89" id="DDI-PubMed.12705168.s4.e0" text="pitavastatin" /></sentence><sentence text=" However, a remarkable metabolic inhibition of atorvastatin was noted in the presence of various medicinal substances"><entity charOffset="47-59" id="DDI-PubMed.12705168.s5.e0" text="atorvastatin" /></sentence><sentence text=" The intrinsic clearance of atorvastatin lactone was 20-fold greater than that of its acid form, whereas no marked difference was noted between pitavastatin and its lactone form"><entity charOffset="28-48" id="DDI-PubMed.12705168.s6.e0" text="atorvastatin lactone" /><entity charOffset="144-156" id="DDI-PubMed.12705168.s6.e1" text="pitavastatin" /><entity charOffset="165-172" id="DDI-PubMed.12705168.s6.e2" text="lactone" /><pair ddi="false" e1="DDI-PubMed.12705168.s6.e0" e2="DDI-PubMed.12705168.s6.e0" /><pair ddi="false" e1="DDI-PubMed.12705168.s6.e0" e2="DDI-PubMed.12705168.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12705168.s6.e0" e2="DDI-PubMed.12705168.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12705168.s6.e1" e2="DDI-PubMed.12705168.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12705168.s6.e1" e2="DDI-PubMed.12705168.s6.e2" /></sentence><sentence text=" Pitavastatin lactone showed no inhibitory effect on CYP3A4-mediated metabolism of testosterone in contrast to atorvastatin lactone"><entity charOffset="1-21" id="DDI-PubMed.12705168.s7.e0" text="Pitavastatin lactone" /><entity charOffset="83-95" id="DDI-PubMed.12705168.s7.e1" text="testosterone" /><entity charOffset="111-131" id="DDI-PubMed.12705168.s7.e2" text="atorvastatin lactone" /><pair ddi="false" e1="DDI-PubMed.12705168.s7.e0" e2="DDI-PubMed.12705168.s7.e0" /><pair ddi="false" e1="DDI-PubMed.12705168.s7.e0" e2="DDI-PubMed.12705168.s7.e1" /><pair ddi="false" e1="DDI-PubMed.12705168.s7.e0" e2="DDI-PubMed.12705168.s7.e2" /><pair ddi="false" e1="DDI-PubMed.12705168.s7.e1" e2="DDI-PubMed.12705168.s7.e1" /><pair ddi="false" e1="DDI-PubMed.12705168.s7.e1" e2="DDI-PubMed.12705168.s7.e2" /></sentence><sentence text=" These results suggest that pitavastatin and its lactone form will be highly unlikely to interact with other drugs in clinical practice"><entity charOffset="28-40" id="DDI-PubMed.12705168.s8.e0" text="pitavastatin" /><entity charOffset="49-56" id="DDI-PubMed.12705168.s8.e1" text="lactone" /><pair ddi="false" e1="DDI-PubMed.12705168.s8.e0" e2="DDI-PubMed.12705168.s8.e0" /><pair ddi="false" e1="DDI-PubMed.12705168.s8.e0" e2="DDI-PubMed.12705168.s8.e1" /></sentence><sentence text="" /></document>